Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 0.73 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520330 | 0.86 | RXRA (0.76) | MAOBPARP10ALDH1A1MAPTMAPK1 | |
| SCHEMBL16550312 | 0.86 | RXRA (0.76) | MAOBPARP10ALDH1A1MAPTMAPK1 | |
| SCHEMBL933577 | 0.86 | MAOB (0.76) | MAOBMAOAALDH1A1MAPTHTT | |
| SCHEMBL16395775 | 0.85 | MAOB (1.00) | MAOBMAOAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2087139 | 0.85 | MAOB (1.00) | MAOBMAOAPARP10ALDH1A1HTT | |
| SCHEMBL9778577 | 0.85 | MAOB (1.00) | MAOBMAOAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL13513249 | 0.84 | MAOB (0.87) | MAOBMAOAALDH1A1MAPTHTT | |
| SCHEMBL42302 | 0.84 | MAOB (1.00) | MAOBMAOAPARP10ALDH1A1HTT | |
| SCHEMBL18477942 | 0.84 | L3MBTL1 (0.75) | MAOBALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL6959174 | 0.83 | NPC1 (0.73) | MAOBMAOAALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109528716-B | Application of chalcone compound containing carboxymethyl rhodanine structure | 延边大学 | 2021-02-02 | — | — | CN | disclosed |
| CN-109528716-A | The application of the chalcone compounds of the structure of rhodanine containing carboxymethyl | 延边大学 | 2019-03-29 | — | — | CN | disclosed |
| US-8153634-B2 | Carbinol derivatives having cyclic linker | KOWA COMPANY, LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-2281817-A1 | SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER | Kowa Company, Ltd. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-0288297-B1 | OPTICALLY ACTIVE BENZENE DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
| US-5063197-A | Aromatic compound | MITSUBISHI PAPER MILLS LIMITED (JP) | 1991-11-05 | — | — | US | disclosed |
| US-4985590-A | Optically active benzene derivatives and process for preparation thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-01-15 | — | — | US | disclosed |
| EP-0288297-A2 | Optically active benzene derivatives and process for preparation thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | NR1H2, NR1H3, LDLR | MAOB 3598/4885MAOA 4103/4885PARP10 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.